modelPrimaquine
Extends from Pharmacolibrary.Drugs.ATC.P.P01BA03.
Information
| name: | Primaquine | |
| ATC code: | P01BA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 2.68 | L |
| clearance: | 21.8 | L/h |
| other parameters in model implementation | ||
Primaquine is an 8-aminoquinoline antimalarial drug primarily used for the radical cure of Plasmodium vivax and Plasmodium ovale malaria by eradicating hepatic hypnozoites. It is also indicated in the treatment and prevention of Pneumocystis jirovecii pneumonia. Primaquine is approved and in clinical use today for malaria treatment, especially for prevention of malaria relapses.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers taking oral primaquine, both sexes, median age around 25-35 years.
References
Carag, JH, et al., & Bronson, E (2021). PHARMACOKINETICS OF PRIMAQUINE PHOSPHATE AFTER A SINGLE ORAL ADMINISTRATION TO AFRICAN PENGUINS (. Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians 52(1) 75–80. DOI:10.1638/2020-0172 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33827163
Chairat, K, et al., & Tarning, J (2018). Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. The Journal of antimicrobial chemotherapy 73(11) 3102–3113. DOI:10.1093/jac/dky297 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30085149
Kulkarni, SP, et al., & Gogtay, NJ (2013). Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. Indian journal of pharmacology 45(4) 330–333. DOI:10.4103/0253-7613.114997 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24014905
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)